Actionable Genome Consortium to guide NGS in cancer

    Four major cancer institutes have joined Illumina to set up a program that helps oncologists diagnose, classify and treat cancer using next-generation sequencing. The Actionable Genome Consortium (AGC) brings together the San Diego–based sequencing giant with the Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center and Fred Hutchinson Cancer Research Center. The aim is to define genomic changes in patients' tumors that will allow oncologists to choose optimal therapies and testing strategies. The hope is that defining an 'actionable tumor' will support new diagnostics development and regulatory oversight for genomic testing in cancer.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Actionable Genome Consortium to guide NGS in cancer. Nat Biotechnol 32, 965 (2014). https://doi.org/10.1038/nbt1014-965d

    Download citation